| NCT00216515 | Janssen Korea, Ltd., Korea | Alzheimer Disease | 2004-03 | PHASE4 |
| NCT00261573 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease|Vascular Dementia | 1998-12 | PHASE3 |
| NCT00035204 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. | Alzheimer Disease | | PHASE4 |
| NCT02234752 | Sheppard Pratt Health System | Schizophrenia|Schizoaffective Disorder | 2014-09 | PHASE2 |
| NCT01100775 | University of Maryland, Baltimore|National Institute of Mental Health (NIMH) | Schizophrenia | 2010-05 | PHASE2 |
| NCT00304629 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease | 2000-03 | PHASE3 |
| NCT01531153 | Yale University|National Institute on Drug Abuse (NIDA) | Addiction | 2011-09 | NA |
| NCT00211588 | Memorial Hospital of Rhode Island|Ortho-McNeil Neurologics, Inc. | Parkinson´s Disease | 2004-06 | NA |
| NCT00750529 | University Hospital, Clermont-Ferrand|Janssen-Cilag Farmaceutica Ltda. | Alzheimer´s Disease | 2008-11 | PHASE1 |
| NCT01190748 | Actavis Inc. | Healthy | 2004-11 | PHASE1 |
| NCT00297362 | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Alzheimer Disease | 2004-06 | |
| NCT01129479 | University of North Carolina, Chapel Hill|Ortho-McNeil Neurologics, Inc. | Aphasia|Stroke | 2004-10 | NA |
| NCT00161044 | University of Maryland, Baltimore | Chronic Schizophrenia | 2004-09 | NA |
| NCT00679627 | Janssen Research & Development, LLC | Alzheimer´s Disease | 2008-06 | PHASE3 |
| NCT00423969 | Indiana University | Depression | 2003-11 | PHASE4 |
| NCT00176423 | University of Maryland, Baltimore|Stanley Medical Research Institute|Ortho-McNeil Neurologics, Inc. | Schizophrenia|Schizoaffective Disorder | 2002-05 | PHASE4 |
| NCT07208344 | Anhui Provincial Hospital|Shandong Qilu Stem Cell Engineering Co., Ltd. | Alzheimer Disease (AD) | 2025-07-31 | EARLY_PHASE1 |
| NCT00814658 | Janssen-Cilag Farmaceutica Ltda. | Dementia | 2008-06 | PHASE4 |
| NCT01029132 | Samsung Medical Center|Janssen Korea, Ltd., Korea | Dementia | 2007-04 | NA |
| NCT01194336 | U.S. Army Medical Research and Development Command|Walter Reed Army Institute of Research (WRAIR) | Biomarkers, Pharmacological | 2012-02 | |
| NCT03014323 | Vanderbilt University Medical Center | Insulin Sensitivity|Oxidative Stress | 2017-01 | PHASE1 |
| NCT00181675 | Massachusetts General Hospital | ADHD | 2002-12 | PHASE4 |
| NCT02374567 | Hannover Medical School | Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders | 2015-01 | PHASE3 |
| NCT02420327 | University of Maryland, Baltimore | Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor | 2014-09 | NA |
| NCT00216593 | Janssen Pharmaceutica N.V., Belgium | Dementia|Alzheimer Disease | 2003-12 | PHASE3 |
| NCT07284290 | Virginia Commonwealth University|National Institute of Neurological Disorders and Stroke (NINDS) | Dementia With Lewy Bodies|Parkinson Disease Dementia|Healthy Controls | 2025-12-08 | PHASE4 |
| NCT00320736 | North Suffolk Mental Health Association|Janssen Medical Affairs | Schizophrenia|Schizoaffective Disorder | 2004-01 | PHASE4 |
| NCT02872857 | The University of Texas Health Science Center, Houston | Subarachnoid Hemorrhage | 2016-09 | PHASE1|PHASE2 |
| NCT01012167 | University of Maryland, Baltimore|National Institute of Mental Health (NIMH) | Schizophrenia | 2010-02 | PHASE2 |
| NCT00523666 | Ludwig-Maximilians - University of Munich | Alzheimer´s Disease | 2006-09 | PHASE4 |
| NCT00645190 | Xian-Janssen Pharmaceutical Ltd. | Alzheimer Disease | 2004-03 | PHASE3 |
| NCT00301574 | Janssen Pharmaceutical K.K. | Alzheimer Disease | 2001-04 | PHASE3 |
| NCT00195845 | Cambridge Health Alliance|Northwestern University | Bipolar Disorder | 2003-04 | PHASE4 |
| NCT00240695 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases | 2003-05 | PHASE3 |
| NCT01417429 | Yale University|National Institute on Drug Abuse (NIDA) | Smoking|Tobacco Withdrawal | 2010-03 | PHASE1 |
| NCT00227994 | University of Pittsburgh|National Institute of Mental Health (NIMH) | Cerebrovascular Accident | 2003-04 | PHASE4 |
| NCT01880099 | Yale University|National Institute on Drug Abuse (NIDA) | Nicotine Dependence | 2013-12 | NA |
| NCT07003386 | Shanghai Yueyang Integrated Medicine Hospital | Acute Ischemic Stroke AIS | 2025-09-15 | PHASE2|PHASE3 |
| NCT04769206 | Vanderbilt University Medical Center | Endothelial Dysfunction | 2021-12-20 | PHASE1|PHASE2 |
| NCT00309725 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer´s Disease | | PHASE3 |
| NCT00606801 | Yale University|National Institute on Drug Abuse (NIDA) | Cocaine Abuse | 2007-06 | NA |
| NCT01734395 | Janssen Korea, Ltd., Korea | Alzheimer´s Disease | 2007-03 | |
| NCT00252603 | University of Medicine and Dentistry of New Jersey|National Alliance for Autism Research | Autism|Childhood Autism | 2004-04 | PHASE3 |
| NCT03384784 | University of Pennsylvania|National Institute on Drug Abuse (NIDA) | HIV Associated Cognitive Motor Complex | 2017-10-30 | PHASE2 |
| NCT01039194 | Bristol-Myers Squibb | Alzheimer Disease | 2010-01 | PHASE1 |
| NCT00216502 | Janssen-Cilag S.p.A. | Alzheimer Disease|Dementia|Mental Disorders|Brain Diseases | 2001-08 | PHASE3 |
| NCT02365285 | Vanderbilt University Medical Center|Doris Duke Charitable Foundation | Obesity | 2015-03 | PHASE1|PHASE2 |
| NCT00253214 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease|Dementia | 2001-03 | PHASE3 |
| NCT01669538 | University of Pennsylvania|National Institutes of Health (NIH)|National Cancer Institute (NCI)|National Center for Research Resources (NCRR)|National Institute on Drug Abuse (NIDA) | Tobacco Use Disorder | 2012-08 | PHASE2 |
| NCT00164242 | Caroff, Stanley N., M.D.|Ortho-McNeil Neurologics, Inc. | Tardive Dyskinesia | 2002-01 | PHASE4 |
| NCT00082602 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Ortho-McNeil Neurologics, Inc. | Alzheimer´s Disease | 2004-05 | PHASE3 |
| NCT01009476 | Janssen-Cilag G.m.b.H | Dementia|Alzheimer Disease|Dementia, Vascular | 2006-03 | |
| NCT01181921 | Janssen-Cilag, S.A. | Alzheimer Disease | 2011-05 | PHASE4 |
| NCT03454646 | University Hospital, Bordeaux | Alzheimer Disease|Cholinesterase Inhibitors | 2024-06-01 | PHASE4 |
| NCT00226824 | Parkinson´s Disease and Movement Disorders Center|Ortho-McNeil Neurologics, Inc. | Tourette´s Syndrome|Motor Tic Disorder|Vocal Tic Disorder | 2005-09 | PHASE4 |
| NCT00814801 | Janssen Pharmaceutical K.K. | Alzheimer´s Disease | 2007-02 | PHASE3 |
| NCT00077727 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | 2003-03 | PHASE3 |
| NCT01190761 | Actavis Inc. | Healthy | 2004-12 | PHASE1 |
| NCT00809835 | Yale University|National Institute on Drug Abuse (NIDA) | Cocaine Dependence | 2007-12 | PHASE2 |
| NCT02283242 | University of Sao Paulo|University of Nove de Julho|Feinstein Institute for Medical Research | Abdominal Obesity Metabolic Syndrome | 2014-03 | PHASE4 |
| NCT00035191 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Dementia, Vascular | 2001-10 | PHASE3 |
| NCT01677754 | Hoffmann-La Roche | Alzheimer´s Disease | 2012-10-24 | PHASE2 |
| NCT01548638 | University of Pennsylvania | Nicotine Addiction | 2012-02 | PHASE2 |
| NCT01478633 | Janssen Pharmaceutical K.K. | Alzheimer´s Disease | 2011-09 | PHASE4 |
| NCT00253188 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease|Dementia | 1997-02 | PHASE3 |
| NCT00236431 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Dementia|Alzheimer Disease | 2001-05 | PHASE3 |
| NCT00645554 | Xian-Janssen Pharmaceutical Ltd. | Pharmacokinetics | | PHASE1 |
| NCT00253201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease|Dementia | | PHASE3 |
| NCT02098824 | Amsterdam UMC, location VUmc | Mild Cognitive Impairment (Vascular)|Mild Cognitive Disorder (Vascular)|Vascular Dementia | 2014-02 | PHASE2|PHASE3 |
| NCT03124355 | Vanderbilt University Medical Center | Postural Tachycardia Syndrome | 2017-09-30 | PHASE1 |
| NCT01416948 | INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|U.S. Army Medical Research and Development Command | Posttraumatic Stress Disorder|Traumatic Brain Injury | 2011-08 | PHASE2 |
| NCT00232349 | Seattle Institute for Biomedical and Clinical Research | Schizophrenia|Psychotic Disorder | 2005-02 | PHASE4 |
| NCT00509067 | Georgetown University|National Institute of Mental Health (NIMH)|Washington D.C. Veterans Affairs Medical Center | Schizophrenia | 2007-11 | PHASE2 |
| NCT00741598 | Icahn School of Medicine at Mount Sinai|National Institute of Mental Health (NIMH)|Massachusetts General Hospital | Bipolar Disorder | 2008-09 | PHASE4 |
| NCT00299676 | Janssen-Cilag Pty Ltd | Alzheimer Disease|Dementia|Galantamine | 2005-05 | |
| NCT01921972 | Charite University, Berlin, Germany|German Federal Ministry of Education and Research | Alzheimer´s Disease | 2004-11 | PHASE4 |
| NCT00253227 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Alzheimer Disease|Dementia | 1997-07 | PHASE3 |
| NCT00416169 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Frontotemporal Dementia|Pick Complex | 2003-05 | PHASE2 |
| NCT01054976 | Janssen Korea, Ltd., Korea | Alzheimer´s Disease | 2006-10 | PHASE4 |
| NCT00230997 | Neurological Research Center|Ortho-McNeil Neurologics, Inc. | Lewy Body Disease | 2002-12 | PHASE3 |
| NCT03547622 | Yale University|National Institute on Drug Abuse (NIDA) | Methadone or Buprenorphine Detoxoxification | 2018-05-01 | EARLY_PHASE1 |
| NCT00338117 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Shire | Alzheimer´s Disease|Dementia | 1995-08 | PHASE3 |
| NCT00463879 | Yale University|National Alliance for Research on Schizophrenia and Depression | Schizophrenia | 2005-09 | PHASE2|PHASE3 |
| NCT00969696 | Yale University|National Institute on Drug Abuse (NIDA)|US Department of Veterans Affairs | Memory | 2009-08 | PHASE1 |
| NCT01362686 | Indiana University|Agency for Healthcare Research and Quality (AHRQ) | Dementia|Alzheimer´s Disease | 2011-04 | NA |
| NCT00000172 | Janssen, LP | Alzheimer Disease | | PHASE3 |